$21.75
-1.74 (-7.41%)
Open$23.33
Previous Close$23.49
Day High$23.55
Day Low$21.72
52W High$34.39
52W Low$6.69
Volume—
Avg Volume2.40M
Market Cap3.96B
P/E Ratio—
EPS$-0.84
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+29.8% upside
Current
$21.75
$21.75
Target
$28.24
$28.24
$22.54
$28.24 avg
$42.65
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 90.54M | 66.63M | 421.41M |
| Net Income | -147,466,626 | -97,667,203 | -114,600,480 |
| Profit Margin | -162.9% | -154.7% | -27.2% |
| EBITDA | -158,223,967 | -110,613,561 | -127,773,532 |
| Free Cash Flow | — | — | -89,915,808 |
| Rev Growth | +35.9% | +35.9% | +7.1% |
| Debt/Equity | — | — | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |